FDA rejects Spectrum’s lung cancer drug poziotinib
pharmaphorum
NOVEMBER 25, 2022
The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea’s Hanmi Pharma, which originally developed the drug. The post FDA rejects Spectrum’s lung cancer drug poziotinib appeared first on.
Let's personalize your content